Notice of Results

Hutchison China Meditech Limited
26 July 2006


For Immediate Release                                               26 July 2006

                     Hutchison China Meditech Limited ('Chi-Med')

                          Notice of Maiden Interim Results

Chi-Med, the phamaceutical and healthcare group based primarily in China, will
be announcing its maiden interim results for the six months ended 30 June 2006
on Wednesday 9 August 2006.

An analyst presentation will be held at 9.30am on the day, at Citigate Dewe
Rogerson, 3 London Wall Buildings, London, EC2M 5SY.

Enquiries:

Citigate Dewe Rogerson     [phone]
Yvonne Alexander


About Chi-Med


Chi-Med is the holding company of a pharmaceutical and healthcare group based
primarily in China and is listed on the Alternative Investment Market of the
London Stock Exchange.


Chi-Med conducts pharmaceutical research and development of botanical drugs,
semi-synthetic natural product drugs, and synthetic single chemical entity drugs
through its wholly owned Hutchison MediPharma subsidiary. Hutchison MediPharma
aims to bring novel drugs to the global market for the treatment of cancer and
auto-immune diseases by using modern drug discovery and development technologies
and clinical standards that meet the requirements of ICH guidelines.


Chi-Med is majority owned by Hutchison Whampoa Limited, an international
corporation listed on the Main Board of the Hong Kong Stock Exchange.


                      This information is provided by RNS
            The company news service from the London Stock Exchange